- Home
- RNAC vs ZNTL Comparison
RNAC vs ZNTL Comparison
Compare RNAC & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNAC | ZNTL |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | 75 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.2M | 156.7M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RNAC | ZNTL |
|---|---|---|
| Price | $5.80 | $2.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $35.00 | $6.60 |
| AVG Volume (30 Days) | 174.9K | ★ 543.2K |
| Earning Date | 03-09-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,797,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.98 | $1.01 |
| 52 Week High | $14.56 | $3.95 |
Technical Indicators
Market Signals| Indicator | RNAC | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 38.84 |
| Support Level | N/A | $2.10 |
| Resistance Level | $8.10 | $2.69 |
| Average True Range (ATR) | 0.56 | 0.23 |
| MACD | -0.19 | -0.04 |
| Stochastic Oscillator | 5.57 | 0.42 |
Price Performance
Historical ComparisonAbout RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.